Common Name(4as,6r)-4a-hydroxy-l-erythro-5,6,7,8-tetrahydrobiopterin
DescriptionTetrahydrobiopterin (BH4) is essential for catalyzing the conversion of phenylalanine into tyrosine by phenylalanine hydroxylase. During this physiological reaction, the oxidation of BH4 creates 4a-hydroxytetrahydropterin (CAS: 70110-58-6) intermediates and hydrogen peroxide is formed. The hydrogen peroxide and the hydroxytetrahydropterin can both be derived from alternate breakdown routes of a common precursor, the corresponding 4a-hydroperoxytetrahydropterin (PMID: 8323303 ).
Structure
Molecular FormulaC9H15N5O4
Average Mass257.25000
Monoisotopic Mass257.11240
IUPAC Name2-amino-6-(1,2-dihydroxypropyl)-4a-hydroxy-4,4a,5,6,7,8-hexahydropteridin-4-one
Traditional Name2-amino-6-(1,2-dihydroxypropyl)-4a-hydroxy-5,6,7,8-tetrahydropteridin-4-one
CAS Registry Number1379003-93-6
SMILESC[C@H](O)[C@H](O)[C@H]1CNC2=NC(N)=NC(=O)[C@]2(O)N1
InChI IdentifierInChI=1S/C9H15N5O4/c1-3(15)5(16)4-2-11-6-9(18,14-4)7(17)13-8(10)12-6/h3-5,14-16,18H,2H2,1H3,(H3,10,11,12,13,17)/t3-,4+,5-,9-/m0/s1
InChI KeyKJKIEFUPAPPGBC-XXKOCQOQSA-N
CHEBI IDCHEBI:15642
HMDB IDHMDB0002281
Pathways
NameSMPDB/PathBank
Tyrosine metabolism
Tryptophan metabolism
Phenylalanine and Tyrosine Metabolism
Alkaptonuria
Hawkinsinuria
Phenylketonuria
Tyrosinemia Type I
Tyrosinemia Type 2 (or Richner-Hanhart syndrome)
Tyrosinemia Type 3 (TYRO3)
Disulfiram Action Pathway
Tyrosinemia, transient, of the newborn
Dopamine beta-hydroxylase deficiency
Monoamine oxidase-a deficiency (MAO-A)
StateSolid
Water Solubility4.81e+00 g/l
logP-2.29
logS-1.73
pKa (Strongest Acidic)9.81
pKa (Strongest Basic)3.85
Hydrogen Acceptor Count9
Hydrogen Donor Count6
Polar Surface Area152.56 Ų
Rotatable Bond Count2
Physiological Charge0
Formal Charge0
Refractivity58.60 m³·mol⁻¹
Polarizability24.20

We require the use of cookies for essential features like storing your previously submitted BASys2 queries. Rejecting the usage of cookies will result in certain features being disabled. By clicking ACCEPT or continuing to use the website you are agreeing to our use of cookies.

ACCEPT